相关实验视频

Updated: May 22, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

[由抗体与药物合物诱导的扩散性间歇性肺病]

L Maurier¹, A-L Chéné², P Hulo³

¹Service de pneumologie, hôpital Laennec, CHU de Nantes, boulevard Professeur-Jacques-Monod, 44800 Saint-Herblain, France.

Revue des maladies respiratoires

|April 22, 2025

概括

抗体-药物合物 (ADCs) 在非小细胞肺癌 (NSCLC) 中表现有前途,但可以引起间歇性肺病 (ILD). 风险因素和早期检测是控制这种肺毒性的关键.

科学领域:

在瘤学瘤学.
肺部医学肺部医学
药理学药理学是指药理学的学科.

背景情况:

抗体-药物合物 (ADC) 是治疗非小细胞肺癌 (NSCLC) 的新兴疗法.
肺毒性,特别是间歇性肺病 (ILD),是与ADCs相关的公认不良事件.
针对不同标记物的几种ADC正在进行NSCLC治疗的研究.

研究的目的:

在NSCLC患者中审查ADC诱导的间歇性肺病 (ILD) 的发生率和危险因素.
强调了解各种ADC的肺毒性概况的重要性.
强调需要在接受ADC的患者中及时检测和管理ILD.

主要方法:

对已发表的研究和临床试验数据的综述关于NSCLC中ADCs.
分析不同ADC的ILD报告发病率.
识别与ADC诱导的ILD相关的潜在风险因素.

主要成果:

药物诱导ILD的发病率在不同的ADC之间有很大的差异,在一些研究中从0%到25%以上.
特拉斯图苏巴-德鲁克斯坦 (Her-2) 和达托帕塔巴-德鲁克斯坦 (TROP-2) 已经显示出显著的ILD率.
风险因素可能包括先前存在的呼吸道疾病,功能障碍和特定的ADC特征 (类型,剂量).

结论:

在NSCLC的发展过程中,多个ADC具有引起ILD的风险.
早期识别和管理策略对于减轻ADC诱导的ILD的严重程度至关重要.
需要进一步的研究,特别是关于ADC与免疫治疗结合的肺毒性.

关键词:

抗体与药物的结合物.没有小细胞的肺癌.非小细胞肺癌的癌症结合的抗体药物-药物.风险因素风险因素肺部疾病间歇性肺部疾病肺部病变间隔性间隔性风险因素风险因素有毒性有毒性有毒性有毒性

更多相关视频

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...